Loading...

PODCAST

The Pharma Closeout | Daily Pharmaceutical and Biotech News in 15 Minutes

Your daily pharmaceutical news briefing — FDA decisions, clinical trial results, biotech M&A, and drug pipeline updates in under 15 minutes, every weekday. Hosted by Alex Mercer and Maya Patel. Plus a Week in Review every Sunday synthesizing the week"s biggest moves in pharma and biotech. Covering drug approvals, licensing and M&A deals, biopharma investing, and healthcare market intelligence. Smart, fast, and built for pharma and biotech professionals who need to stay ahead. Transcripts,

science life sciences

All Episodes

00:09:19

Biohaven Faces FDA Enrollment Hold & AbbVie Reports...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/09/11

Biohaven's FDA partial hold pauses new epilepsy-trialenrollment; the company still expects RISE-3 results this year. AbbVie reports LUNA menstrual-migraine results for oral Qulipta (atogepant), while Shionogi misses a stroke endpoint and Disc Medicine reports fewer blood-removalprocedures in early polycythemia vera data. Novartis faces shareholder pressure, Solstice raises $225 million, and MannKind partners with Rose Pharma on inhaled weight management. NICE questions the value of Gilead's

en-us

00:12:15

Bayer's Hyrnuo Enters First-Line Rivalry & FDA Gets...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/09/10

Bayer's Hyrnuo (sevabertinib) gains first-line accelerated approval in HER2-mutant lung cancer, joining an established rival. Permanent FDA center leaders follow repeated turnover, while Structure's experimental obesity pill aleniglipron adds 72-week follow-up without a concurrent placebo. Kura, EMD Serono and Encoded back new development efforts; Tyra reports early bladder cancer responses, Evommune changes its eczema program, and Beeline advances lupus studies. BioMarin's Voxzogo (vosoritide)

en-us

00:10:28

Novartis's HARBOR Miss Tests Confidence in the Growth...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/09/09

Novartis's del-desiran missed HARBOR's primary endpoint in myotonic dystrophy, adding pressure to a growth plan already facing setbacks. Roivant and Pulmovant's mosliciguat data advance Monday's PHocus preview, while AstraZeneca, Pharvaris, Amgen, Inhibrx and Bristol Myers add clinical updates across lung disease, hereditary angioedema and cancer. BrainChild Bio's financing, the proposed Sernova-Seraxis merger and Intellia's lonvo-z Priority Review round out the slate. Two resolved Rasonque access

en-us

00:09:18

Novo Ends Two Ziltivekimab Heart-Failure Trials &...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/09/08

Novo is ending the HERMES and ATHENA ziltivekimab trials after a monitoring committee judged them unlikely to succeed, leaving ARTEMIS as its remaining Phase 3 cardiovascular path. We examine ADARx's IPO filing, the Aptar-Aceso ACT-101 collaboration in cystic fibrosis, and STEP Young semaglutide results in children ages six to under twelve. SynAct's resomelagon reanalysis asks what another rheumatoid arthritis trial must prove after two primary-endpoint misses. This late Labor Day edition

en-us

00:18:04

Week in Review | Bristol's CAR-T Pause Was Three...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/09/07

Bristol Myers Squibb told regulators in early June. The rest of us found out this week, after an analyst note. Three months sat between those two facts, and that gap is the story of the week. Also this week, a cardiovascular outcomes trial in more than eight thousand patients missed its endpoint and put a whole drug class in question. A mid-stage lupus readout took fifty five percent off a company in a day. And the FDA approved a cancer drug over its own advisers, while memos surfaced on a second

en-us

00:09:47

Novartis's Pelacarsen Misses—What's Next for Rivals?...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/09/05

Novartis's pelacarsen missed its cardiovascular endpoint despite lowering Lp(a)—what should Amgen and Lilly rethink? FDA accelerated approval brings AstraZeneca's Etcamah (camizestrant) to ESR1-mutated, HR-positive, HER2-negative advanced breast cancer before progression, with confirmatory benefit still required. Following Monday's CAR-T coverage, new reporting traces Bristol Myers Squibb's notifications to early June, months before public confirmation. Also: Revolution

en-us

00:08:29

AbbVie's Etentamig Clears Phase 3 Myeloma Trial on...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/09/04

AbbVie's BCMA x CD3 bispecific etentamig met both primary endpoints in the Phase 3 CERVINO myeloma study — a 74.0% response rate versus 45.7% for standard therapy and a 60% reduction in the risk of progression or death — with a safety profile AbbVie is positioning for outpatient and community care. GSK is paying HUTCHMED $110 million upfront — up to $1.295 billion in total — for HMPL-A830, a dual KRAS/EGFR antibody-targeted conjugate whose global Phase 1 hasn't started yet. Also: the FDA

en-us

00:13:14

uniQure Files Huntington's Gene Therapy — FDA...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/09/03

uniQure filed AMT-130 for FDA and UK approval on three-year Phase 1/2 data with a propensity-matched external control, and a potential accelerated-approval action date in late April or early May 2027. The same day, Ultragenyx's Phase 3 Aspire study of apazunersen in Angelman syndrome missed both its primary and key secondary endpoints, and Akeso reported that ivonescimab met overall survival against pembrolizumab in first-line PD-L1-positive lung cancer. Also: Teva's anti-IL-15 antibody hits

en-us

00:10:30

Alumis TYK2 Pill Fails Lupus: What's Left of the...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/09/02

Alumis shares fell 55% after envudeucitinib missed every endpoint in a mid-stage systemic lupus study - and the CEO still sees a path to Phase 3 built on a prespecified interferon-high subgroup. We unpack what that pivot costs and why the whole TYK2 class is now a show-me story outside psoriasis. Also: Roche pays Simcere Zaiming $75 million upfront in a deal worth up to $1.53 billion for trispecific CD79a/CD19/CD3 antibody SIM0660, and Novartis's Rhapsido (remibrutinib) clears two Phase 3

en-us

00:11:49

Novartis, BMS Halt Autoimmune CAR-T Trials on Safety...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/09/01

Two of the biggest names in cell therapy just hit the brakes on the most ambitious idea in immunology - Novartis and Bristol Myers Squibb have paused their autoimmune CAR-T trials after serious immune reactions, with trade press reporting three deaths in CAR-T trials. Also today: nine more drugmakers sign on to most-favored-nation pricing, and the FDA hands down two blood-disorder approvals in one week - Takeda's Mimrylo and PharmaEssentia's Besremi - that just turned the myeloproliferative

en-us

00:13:28

Week in Review | AstraZeneca's Wainua Missed in...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/08/31

Three hundred eighty-one events versus three hundred ninety-two — AstraZeneca and Ionis's Wainua (eplontersen) missed in ATTR-CM, and the Munich post-mortem points at background therapy, not the molecule. With roughly four in five patients on a stabilizer, the trial answered an add-on question it was never built to ask — while at the same congress Alnylam put up a prespecified HELIOS-B subgroup of vutrisiran by baseline tafamidis use (259 of 654 randomized and treated patients), published in the

en-us

00:10:38

Cytokinetics Wins Non-Obstructive HCM, Stock Falls...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/08/29

Cytokinetics' aficamten hit both primary endpoints in non-obstructive hypertrophic cardiomyopathy — a 3.0-point symptom score gain — and the stock still fell about 6%. We break down what that effect size means for the Q4 sNDA and the pricing fight ahead, plus Moderna's upsized $2.6 billion convertible for oncology, BioNTech and Genentech terminating a Phase 2 of autogene cevumeran after a survival imbalance, and Roche's $45 million upfront for DualityBio's DUPAC ADC payload platform

en-us

00:10:28

Roivant's JAK1/TYK2 Pill Wins First Dermatomyositis...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/08/28

Roivant and Priovant won FDA approval for LISRAYA (brepocitinib) in dermatomyositis — 55% of patients achieved both symptom improvement and minimal steroid use at 52 weeks. But the label carries a full JAK boxed warning, which makes the steroid-sparing case the entire commercial argument. Also: Spyre Therapeutics' anti-TL1A antibody missed in rheumatoid arthritis, erasing more than $1 billion in market value; Amgen and AstraZeneca's Tezspire (tezepelumab) hit all endpoints in Phase 3

en-us

00:09:02

Revolution Medicines' RAS Inhibitor Cleared in Five...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/08/27

Revolution Medicines filed on July 22nd and had FDA approval just over a month later — a five-week review for a pancreatic cancer drug that nearly doubled median survival. Rasonque (daraxonrasib) showed 13.2 months versus 6.7 on chemotherapy in Phase 3 and cleared under the Commissioner's National Priority Voucher program, with RBC modeling roughly $11.5 billion in peak sales for a company that has never commercialized a product. Also in this episode: Spyre Therapeutics shares fell 13% after

en-us

00:09:35

Jazz’s HER2 Bispecific Wins First-Line Gastric &...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/08/26

The FDA cleared Jazz Pharmaceuticals' Ziihera (zanidatamab) in first-line HER2-positive gastroesophageal adenocarcinoma with median overall survival of 26.4 months — but the second regimen on that same label has never shown a significant survival benefit, and the analysis that settles it is due by the end of September. Alex and Maya dig into the label breadth the FDA granted, the boxed warning for diarrhea, and the $250 million milestone Zymeworks just banked on approval. Plus: McKesson buys

en-us

00:10:37

Regenxbio Plunges 26% as FDA Halts Hunter Gene...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/08/24

Regenxbio shares plunged 26% to $7.96 after the FDA placed a second clinical hold on RGX-121 (clemidsogene lanparvovec) — but the real trigger was the company abandoning its Hunter syndrome BLA resubmission. Spine MRI findings in five CAMPSIITE participants dosed three to six years ago surfaced through expanded monitoring Regenxbio built itself. Also: Roche's Genentech pays Hanmi $190 million up front, up to $2.3 billion total, for UCN2 analog HM17321 in muscle-sparing obesity; courts reject

en-us

00:10:30

Week in Review | AstraZeneca Kills Volrustomig Lung...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/08/23

AstraZeneca pulled its Phase 3 volrustomig lung trial at interim review — and released no efficacy data at all. The eVOLVE-Lung02 study tested the PD-1 by CTLA-4 bispecific plus chemotherapy against pembrolizumab plus chemo in first-line PD-L1-low non-small cell lung cancer, and the monitoring committee called both co-primary endpoints unlikely to hit. We unpack what survives in mesothelioma, cervical and head and neck, and why an unpublished failure costs the whole field twice. Also: LEO

en-us

00:08:41

Akeso's Third ADC: What "Differentiated" Still Has to...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/08/22

Akeso cleared AK157D1, a B7-H3 antibody-drug conjugate, into Phase 1 in solid tumors — its third differentiated ADC, and a late entry into an already crowded target. Alex and Maya argue whether three assets from one engine is platform depth or correlated risk, and why the dose-escalation ceiling matters more than any early response rate. Also: Leads Biolabs' opamtistomig, a PD-L1/4-1BB bispecific, has an NDA accepted by China's NMPA and is positioned as the first approved 4-1BB-targeting

en-us

00:08:53

Daily Roundup | Moderna and Merck's mRNA Cancer...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/08/21

Intismeran autogene plus KEYTRUDA met its primary and key secondary endpoints in the 1,137-patient Phase 3 INTerpath-001 melanoma trial — the first Phase 3 win for a neoantigen mRNA cancer therapy — as Moderna added roughly $44 billion in market value in a single session. Also: FDA approves Regeneron's Pasatru for fibrodysplasia ossificans progressiva at about $1.4 million a year, setting up a fight with Ipsen's Sohonos; Ultragenyx wins its first gene therapy approval for glycogen storage disease

en-us

00:10:07

Daily Roundup | Heidi Overton FDA Pick: What It Means...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/08/20

Trump names Heidi Overton to lead the FDA — and a Republican senator calls part of her record almost disqualifying on day one. We break down the confirmation fight, the regulatory risk to mRNA programs in oncology and immunology, Regeneron's Pasatru (garetosmab) approval for the ultra-rare bone disease fibrodysplasia ossificans progressiva, SK Biopharmaceuticals' Xcopri (cenobamate) patent settlement with MSN Laboratories, and SK Pharmteco's new high-potency API and ADC payload plants in

en-us

169 results

Similar Podcasts

Beyond the Divide

Koala Moon

Planetterrian Daily

Patrick · Nerra Network

NSF’s Discovery Files Podcast

U.S. National Science Foundation

Curious City: Exploring Science and Wonders

Synthetic Universe

Science Busters Podcast

Martin Puntigam, Martin Moder, Florian...